Biogen Inc. said Thursday that it has settled a lawsuit with New Jersey-based Berlex Laboratories over a patent infringement claim related to Avonex, Biogen's flagship drug used to treat multiple sclerosis. Under the settlement agreement, Cambridge, Mass.-based Biogen will pay Berlex $20 million and receive a fully paid up, royalty-free, non-exclusive license under the patents held by Berlex.
January 24, 2002 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers and financiers for the real estate healthcare event of the year!
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Shipman & Goodwin LLP is seeking two associates to expand our national commercial real estate lending practice. Candidates should have ...
Duane Morris LLP seeks a highly motivated junior associate to join its dynamic and growing Labor and Employment Class Action group in Chicag...
Duane Morris LLP has an immediate opening for a mid-level, highly motivated associate to join its dynamic and growing Employment, Labor, Ben...
ShapiroCroland Attorneys at Law Take Pleasure in Announcing that VALERIE A. VLADYKA HAS JOINED THE FIRM AS COUNSEL Valerie concentrates her practice in Insurance coverage, Commercial Litigation and Probate Matters 411 Hackensack Avenue, Hackensack, New Jersey 07601 Telephone: (201) 488-3900 | Telecopier: (201) 488-9481 |www.shapiro-croland.com November 2023
Congratulations to our Partner Richard Segal on becoming Chairman of the Miami Beach Chamber of Commerce
WE'RE MOVING! November 30, 2023
